Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award

Home - Biosciences

Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award

Discovery        News        Contact Us

Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award

 The Randox Discovery, an exciting and unique diagnostic analyser which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High Design Quality.

Red Dot, which has become established as one of the top profile product design awards has roots dating back as far as 1955 and determines the best products created each year. Recognised as one of the largest global product competitions for innovation excellence, this sought-after seal for quality design attracts submissions from over 50 countries, across 49 different categories including medical devices and technology.

 

Dr Stuart Jackson, Randox Project Design Engineer, commented;

“Randox are delighted to have achieved the Red Dot design award, the culmination of five years of development and coordination of engineering design teams spanning two continents. The Discovery is a particularly unique innovation capable of automating Randox Biochip molecular diagnostics assays, from sample lysis and end-point PCR to multiplexing detection, with accessibility and ease-of-use at the forefront of the design.”

Dolmen were briefed by the Randox team to develop a creative and dynamic way to showcase the cutting-edge inner workings of the Discovery. Essentially, to turn the magic of the machine into a piece of theatre; not just a tool, but the centre of attention, a focal point for the lab that has excellent usability and accessibility throughout. Dolmen and Randox collaborated closely to deliver a revolutionary instrument that, amongst its many abilities, is a COVID-19 diagnostic analyser that is the first of its kind.

Chris Murphy, CEO and Design Director, Dolmen Design and Innovation, commented;

“We are delighted that our collaboration with Randox has delivered another Red Dot design award for our team. Randox as a team truly value the power of design and how it can deliver better outcomes for end users. It is also wonderful to see our designs delivering positive change at the frontline of the COVID pandemic. This project was hugely collaborative, and we look forward to more collaborations in the future.”

What makes the Discovery special is its ability to conduct the full testing process, inclusive of sample preparation techniques such as extraction, purification, amplification and detection, in one highly intelligent, fully integrated space. The preparation of COVID-19 samples before testing was once lengthy and time-consuming, requiring a separate, sterilized laboratory for each stage, but can now be conducted on-board and by the fully automated Discovery platform, allowing a single operator to run multiple molecular tests simultaneously.

Combining almost 40 years of diagnostics into one platform, bringing multiple labs into one the COVID-19 diagnostic analyser is the first of its kind to combine sample preparation techniques and Biochip Technology.

Professor Dr. Peter Zec, Red Dot CEO, commented;

 “The winners of the Red Dot Award: Product Design 2021 were particularly impressive this year. The design of their products is excellent, in terms of both the aesthetic and the functionality. It’s not easy to prevail in such a strong field of competitors and to win over our jury. Consequently, I want to congratulate the laureates very sincerely on their success.”

For further information please email randoxpr@randox.com

 

Want to know more?

Contact us or visit our find out more about the Randox Discovery

Related Products

Randox Discovery

COVID 19 Product Overview

COVID 19 QPCR ASSAY

VIRAL RNA EXTRACTION KIT


New 39-minute COVID test available on Randox-Bosch Vivalytic

News       About Us       SARS-CoV-2 Rapid Test

 

02 October 2020

 

New 39-minute COVID test available on Randox-Bosch Vivalytic

  • The world’s fastest PCR based SARS-CoV-2 test for the point of care delivers reliable results in 39 minutes.
  • Has a sensitivity of 98 percent and a specificity of 100 percent.
  • Simultaneous testing of five people with one cartridge by pooling will be available from early October.
  • Work is in progress to further reduce time to result.

A rapid new coronavirus test, which provides results for Covid-19 in just 39 minutes, is now available on the Vivalytic, a point of care platform brought to market by Randox Laboratories and Bosch.

The test for detection of the SARS-CoV-2 pathogen, is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centres at service stations or in airports, so that people who take the test can obtain a reliable result while at the testing site.

Available now in Europe, the CE-approved test, which has a sensitivity of 98 percent and a specificity of 100 percent, helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.

“Rapid and accurate testing plays a crucial role in identifying cases of Covid-19 – to contain any outbreaks and limit the spread of the virus,” says Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences.

 “This new rapid test will be a game-changer in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than ever before.”

Randox and Bosch launched the first rapid test for the Vivalytic analyser at the end of March, after just six weeks’ development.

As a multiplex test, it simultaneously checks samples for the SARS-CoV-2 virus as well as nine other respiratory diseases in two and a half hours, whereas the new accelerated test is exclusively for SARS-CoV-2.

“With our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device – from screening all the way to supporting differential diagnosis for similar symptoms,” says Marc Meier, president of Bosch Healthcare Solutions GmbH.

And development work for Covid tests on the Vivalytic is ongoing: as of early October 2020, by pooling samples together it will be possible to simultaneously evaluate five samples in one test cartridge and at a comparable speed – a world first.

This will increase available testing capacity, by enabling fully automated processing of more than 160 samples a day using a Vivalytic device.

Key Benefits of SARS-CoV-2 test on Vivalytic point of care platform

The advantages of the rapid SARS-CoV-2 test on Vivalytic lie not only in speedy analysis, but also in ease of use. A sample is taken from the nose or throat using a swab, and placed in the test cartridge. Then the cartridge, which contains all the reagents required for the test, is inserted into the Vivalytic device for automated analysis.

  • Turnaround time of 39 mins from sample entry to result.
  • The SARS-CoV-2 rapid test has recently received CE marking.
  • The SARS-CoV-2 pooling test can run up to 5 samples on-board one single cartridge.
  • Easy 4-step user-friendly process from sample entry to result. Minimal training required.
  • Detection from real-time PCR from Nasopharyngeal and/or Oropharyngeal swab.
  • Suitable for use in any laboratory and non-laboratory settings.

The development of the new Vivalytic PCR singleplex test is part of a research and development project funded by the German Federal Ministry of Education and Research (BMBF).

For more information please contact marketing@randox.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Alzheimer’s Disease Month at Randox Biosciences

Randox Biosciences          Immunoassay Arrays          COVID-19

 

15 September 2020

 

Alzheimer’s Risk Array from Randox Biosciences

September 2020 marks the 9th World Alzheimer’s Month

World Alzheimer’s Month is the international campaign every September to raise awareness and challenge the stigma that surrounds dementia. Alzheimer’s Disease is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia. It is defined as an irreversible, progressive brain disorder in which parts of the brain are damaged over time.

According to Alzheimer’s Disease International dementia affects people differently – no two people will experience symptoms in exactly the same way. A person’s personality, general health and social situation are all important factors in determining the impact of dementia on an individual. The most common signs are memory loss, the loss of practical abilities, problems with language, changes in mood and behaviour, and withdrawal from work or social activities.1

Who is affected?

  • There are currently around 850,000 people with dementia in the UK. This is projected to rise to 1.6 million by 2040.2
  • 209,600 will develop dementia this year, that’s one every three minutes.2
  • 1 in 6 people over the age of 80 have dementia.2
  • 70% of people in care homes have dementia or severe memory problems.2
  • There are over 42,000 people under 65 with dementia in the UK.2

The Randox Alzheimer’s Risk Array is a rapid and highly sensitive blood test facilitating direct Apo E genotyping without the need for molecular testing.  Apo E is present in three common isoforms; Apo E2, Apo E3 and Apo E4. Alzheimer’s Disease risk is increased in individuals with the Apo E4 allele.

Apolipoprotein E (ApoE) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. ApoE polymorphic alleles are the main genetic determinants of Alzheimer Disease risk. Presence of ApoE4 allele is associated with increased risk for cerebral amyloid angiopathy and age-related cognitive decline during normal ageing.3

Apo E4 is one of three common isoforms of Apo E and is recognised as a major genetic risk factor the development of Alzheimer’s disease.   Apo E4 triggers inflammatory cascades that cause neurovascular dysfunction, including blood-brain barrier breakdown, leakage of blood-derived toxic proteins into the brain and reduction in the length of small vessels.

Utilising revolutionary patented Biochip Technology, the Randox Alzheimer’s Risk Array provides a unique solution for the measurement of both total apoE and the apo E4 isoform levels from a single patient sample, facilitating the fast and accurate classification of Alzheimer’s disease risk in comparison to brain scanning (CT and MRI).

Key Benefits of Alzheimer’s Risk Array

  • 2-plex testing from a single sample
  • Assist in research and development of potential treatment
  • Early risk detection of disease
  • Small sample volume
  • Fast throughput

Biochip Technology

Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:

  • The biochips are pre-fabricated with discrete test regions (DTR’s)
  • Highly accurate testing
  • Better diagnosis
  • Reduced sample volume
  • Wide test menu
  • Multiple sample types can be used on a Biochip
  • Cost consolidation

Evidence Investigator

The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.

For further information on our early risk detection testing for Alzheimer’s Disease, please email info@randoxbiosciences.com

References

  1. https://www.alz.co.uk/info/early-symptoms
  2. https://www.alzheimers.org.uk/about-us/news-and-media/facts-media
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898682/

 

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Cerebral Array II from Randox Biosciences

Randox Biosciences          Immunoassay Arrays          COVID-19

 

13 August 2020

 

Cerebral Array II from Randox Biosciences

Randox Biosciences’ Cerebral Array II has been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The array harnesses multiplex testing measuring up to five biomarkers simultaneously using a single patient sample with a turnaround time of 2.5 hours. It is suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Our Cerebral Array II offers excellent sensitivity, precision and recovery as well as analytical performance.

Cerebral Array II

  • C-Reactive Protein (CRP)
  • D-Dimer
  • Neuron Specific Enolase (NSE)
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Soluble Tumour Necrosis Factor Receptor I (sTNFRI)

Key Benefits of Cerebral Array II

  • Multiplex testing from a single sample
  • Suitable for human serum, plasma and cerebrospinal fluid (CSF) samples
  • Small sample volume
  • Excellent analytical performance
  • Fast throughput
  • Applicable to fully automated and semi-automated Evidence platforms

Your central nervous system is your body’s control centre which includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your senses to the muscles throughout your body. When this is damaged, triggered by an illness or injury it can disturb many functions including memory, sensation and even a person’s personality.1 Up to 1 billion people (1 in 6 of the world’s population) suffer from neurological disorders from Alzheimer and Parkinson Disease, strokes, multiple sclerosis and epilepsy.2

World Health Organisation (WHO) categorizes neurological disorders in two groups which is shown in the table below3. Group one is classified as neurological disorders in neuropsychiatry which are non-communicable diseases (NCD). NCD is a disease that is not transmissible directly from one person to another. Group two are disorders/injuries with neurological sequelae meaning a pathological condition resulting from a prior disease, injury, or attack.

GROUP ONE GROUP TWO
Epilepsy Cerebrovascular disease
Alzheimer and Other Dementias Neuroinfectious
Parkinson’s Disease Nutritional deficiencies and neuropathies
Multiple Sclerosis Neurological injuries
Migraine

Randox Biosciences can assist in cerebrovascular research by providing innovative diagnostic technology and tests that will continue to revolutionise the healthcare industry and assist in academic research. This technology includes our Evidence Investigator and our Cerebral Array II which can be used to assist in the discovery and research of Cerebral diseases.

Biochip Technology

Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:

  • The biochips are pre-fabricated with discrete test regions (DTR’s)
  • Highly accurate testing
  • Better diagnosis
  • Reduced sample volume
  • Wide test menu
  • Multiple sample types can be used on a Biochip
  • Cost consolidation

Evidence Investigator

The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.

For further information on our Cerebral Array please visit the Randox Biosciences website.

For any other enquiries please email info@randoxbiosciences.com

References:

  1. https://www.healthline.com/health/brain-disorders#types
  2. https://news.un.org/en/story/2007/02/210312-nearly-1-6-worlds-population-suffer-neurological-disorders-un-report
  3. https://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Early Detection of Acute Kidney Injury in COVID-19 patients

Randox Biosciences          Acute Kidney Injury          COVID-19

15 July 2020

 

The Importance of Early Detection of Acute Kidney Injury in COVID-19 patients

Randox are proud to provide an early detection assay, capable of detecting Acute Kidney Injury in COVID-19 positive patients. AKI is an innovative diagnostic tool with the ability to identify four early and highly sensitive markers of kidney injury.

The National Institute for Health and Care Excellence has highlighted that is important that COVID-19 patients are assessed for AKI on admission to hospital or transfer, monitored for AKI throughout their stay and that AKI is managed appropriately if it develops. (NICE, 2020)

The novel test, which includes biomarkers recommended by the U.S. Food and Drug Administration and the European Medicines Agency detects KIM-I, NGAL, Cystatin C, and Clusterin.

Kidney failure associated with COVID-19 is emerging as a common side effect with further studies underway. Early detection to prevent further renal damage, is vital for an individual’s long-term health, wellbeing and overall survival.

The biomarkers on the Randox AKI Biochip have been identified as more sensitive than traditional testing methods, which, based on urine output and levels of serum creatinine, are grossly insensitive and not specific for the accurate diagnosis and monitoring of AKI.

The Randox AKI assay provides results in 2.5 hours. The new testing panel also facilitates increased lab efficiency and reduced sample prep from the laboratory technician. Using just one urine sample, Randox’s patented Biochip Technology tests for all four AKI biomarkers simultaneously, resulting in time and cost saving benefits, which drive towards an increase in clinical performance.

For further information on our Acute Kidney Injury Array please visit the Randox Biosciences website.

For any other enquiries please email info@randoxbiosciences.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Point of care coronavirus test from Randox and Bosch will launch in April 2020

News       About Us        Randox Biosciences

26 March 2020

 

Vivalytic Viral Respiratory Tract Infection Array Detecting SARS-CoV-2 (COVID-19)

A game-changing point of care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch in April 2020.

The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.

Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences, commented;

“This array focuses not only on the identification of the novel coronavirus strain that causes COVID-19, but also nine other respiratory infection targets simultaneously, including Influenza A and B, Sarbecovirus and MERS. The aim is to diagnose patients fast and accurately from a single genetic sample, maximising containment of the virus whilst minimising the spread. With the development of this array onto a fully automated platform, patients can be diagnosed rapidly at point of care locations globally such as pharmacies and doctor surgeries.”

The Viral Respiratory Tract Infection Array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organisation (WHO) and the Centres for Disease Control (CDC).

The target genes for COVID-19 being used on the VRI array represent conserved regions of the genome which have been chosen for their high sensitivity and specificity.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

“We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

The new VRI test will be conducted on Vivalytic a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilises end point PCR.  The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user to run the patient sample.

 

Key Benefits of Vivalytic | Point of Care Platform

  • Fully-automated
  • User friendly
  • No laboratory training required
  • 4 step work flow
  • Minimal contamination risk – fully contained system
  • No peripherals required – hygienic
  • Touchscreen
  • Connects to LIMS (Laboratory Information Management System)
  • Sample Type: Nasopharyngeal Swab
  • Sample Volume: 300µl clinical sample

For more information or to arrange interviews, please contact info@randoxbiosciences.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Multiplex STI assay for 10 sexually transmitted infections receives CE marking

News       About Us        Randox Biosciences

02 March 2020

 

Multiplex assay for 10 sexually transmitted infections receives CE marking

CE marking has been granted to one of the most comprehensive cartridge-based STI tests.

The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology.

Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”

The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size.

Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

“We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

Benefits of the Randox STI assay technology on the Vivalytic system

  • Fully automated, cartridge-based molecular diagnostics.
  • Multiplex technology detects multiple STIs, including co-infections, from a single patient sample.
  • Full molecular workflow of extraction, PCR amplification and detection.
  • A hygiene and space-saving all-in-one solution that does not require additional peripherals such as laptop, keyboard, barcode scanner or filling stations.
  • Ultimate protection of data and valuable sample material thanks to integration of software with instrument that ensures a safe and reliable run.
  • Test results can be presented either in summary or in detailed raw data form.
  • Instantly available results due to easy integration with popular standard IT systems.

The assay tests simultaneously, from one patient sample, for the STIs below;

  • Chlamydia trachomatis (CT)
  • Neisseria Gonorrhoeae (NG)
  • Trichomonas vaginalis (TV)
  • Mycoplasma genitalium (MG)
  • Treponema pallidum (syphilis) (TP)
  • Herpes simplex virus 1 (HSV-1)
  • Herpes simplex virus 2 (HSV-2)
  • Haemophilus ducreyl (HD)
  • Mycoplasma hominis (MH)
  • Ureaplasma urealyticum (UU)

For further information please contact the Randox PR team on 028 9442 2413 or email randoxpr@randox.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Randox actively testing samples for Coronavirus COVID-19

News       About Us        Randox Biosciences

12 February 2020

 

Introducing the COVID-19 Coronavirus Test from Randox

A ground-breaking test for the potentially fatal COVID-19 strain of coronavirus, is available at global health diagnostics company Randox Laboratories.

The test, developed on Randox’s patented Biochip Technology, is as an enhanced multiplex array which includes tests for COVID-19 and nine other respiratory viruses which can display the same symptoms.

The new enhanced Biochip therefore allows clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of COVID-19, and therefore neglect to differentiate between this strain and other respiratory infections.

“We have therefore developed an extended Viral Respiratory Infection Array that tests simultaneously for COVID-19 and nine other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.”

The test is available on the Randox Evidence Investigator with a turnaround time of 5 hours.

Benefits of the new Randox COVID-19 test

  • Quick Turnaround Times (5 hours on Evidence Investigator)
  • Multiplex array differentiates between mild and serious infection
  • Automated and Semi-Automated options available
  • Medium to high throughput (54 samples in 5 hours)

For further information please visit www.randox.com/coronavirus-randox

QNOSTICS

QCMD

BIOSCIENCES


Coronavirus test available at Randox

News       About Us        Randox Biosciences

26 January 2020

 

Introducing the COVID-19 Coronavirus Test from Randox

A ground-breaking test for the potentially fatal COVID-19 strain of coronavirus, is in the final stages of development at global health diagnostics company Randox Laboratories.

The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate COVID-19 testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms.

The new enhanced Biochip will therefore allow clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of COVID-19, and therefore neglect to differentiate between this strain and other respiratory infections.

“Whilst we’re very quickly developing an efficient novel test for this new strain of coronavirus, we are therefore also working on an extended Viral Respiratory Infection Array that will test simultaneously for COVID-19 and a range of other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.”

The test will be available for the Point of Care analyser, the Vivalytic, within 3 hours, and within 5 hours on the Randox Evidence Investigator.

Benefits of the new Randox COVID-19 test

  • Quick Turnaround Times (3 hours on Vivalytic and 5 hours on Evidence Investigator)
  • Multiplex array differentiates between mild and serious infection
  • Automated and Semi-Automated options available

Randox also currently has available a Respiratory Tract Infection Array, which can test for 22 viral and bacterial respiratory infections simultaneously. The test therefore determines the exact cause of your symptoms and differentiates between mild and serious infections, such as coronavirus. This is also available from Randox Health as a Cold, Cough and Flu test.

For further information please visit www.randox.com/coronavirus-randox

For enquiries email marketing@randox.com or to book your Randox Health Cough, Cold and Flu test please ring 0800 2545 130.

Randox is committed to saving and improving lives on a global scale, and will bring you updates on developments on our test for COVID-19 as and when they happen.

QNOSTICS

QCMD

BIOSCIENCES


Metabolic Syndrome Array from Randox Biosciences

News       About Us        Randox Biosciences

20 December 2019

 

Metabolic Syndrome Array from Randox Biosciences

Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes.

According to the NHS, it occurs when a person has three or more of the following measurements1:

  • Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)
  • Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater
  • HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
  • Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater
  • Fasting glucose of 100 mg/dL or greater

Metabolic syndrome is a serious health condition that affects about 23 percent of adults and places them at higher risk of cardiovascular disease, diabetes, stroke and diseases related to atherosclerosis in arterial walls.The underlying causes include obesity, physical inactivity, genetic factors and aging. 3

Randox offers 10 metabolic syndrome biomarkers over 2 panels enabling multiplex testing to be performed on Randox Biochip Technology. One patient sample is required per test enabling multiple results. Biochip Technology powers the Randox Investigator, a semi-automated benchtop immunoassay analyser.

Metabolic Syndrome Array I

  • Ferritin
  • Interleukin-6 (IL-6)
  • Insulin
  • Leptin
  • Plasminogen Activator Inhibitor-1 (PAI-1)
  • Resistin
  • Tumour Necrosis Factor α (TNFα)

Metabolic Syndrome Array II

  • Adiponectin
  • C-reactive Protein (CRP)
  • Cystatin C

Key Benefits of the Metabolic Syndrome Array

 Biochip Array Technology allows multiplex testing from one patient sample

  • Applicable to fully automated and semi-automated Evidence analysers
  • Biochips are ready to use, thus saving time, labour and resources
  • Rapid turnaround time
  • Validated for both serum and plasma samples – suitable for clinical research studies
  • Small sample volume – 100μl to measure all analytes on each array
  • Excellent analytical performance
  • Multi-analyte controls and calibrators
  • Highly efficient use of valuable patient sample banks
  • No non-specific aggregation, which is associated with multi-analyte bead assays
  • Can be used in the investigation of insulin resistance, pro‑thrombotic state, abnormal body fat distribution, pro‑inflammatory state and atherogenic dyslipidaemia

Randox Biochip Technology is an intelligent chemically activated 9x9mm ceramic biochip which acts as a solid phase reaction vessel. The biochip is spotted with multiple antibodies offering multiplex testing.

The good news is that if you discover that your metabolic health is sub-optimal you can improve it through a combination of diet, exercise and lifestyle adjustments from 30 minutes of moderate to intense exercise 5-7 times a week to quitting smoking and limiting your alcohol intake.

Randox can assist your metabolic research by providing innovative diagnostic technology and tests that will continue to revolutionise the healthcare landscape and assist in academic research. This technology includes our Evidence Investigator and our Metabolic Syndrome Array I and Array II which can be used to assist you in the discovery and research of Metabolic diseases.

For more information visit Randox Biosciences or email info@randoxbiosciences.com

 References

1 https://www.nhs.uk/conditions/metabolic-syndrome/

2http://www.heart.org/en/health-topics/metabolic-syndrome/about-metabolic-syndrome

3 https://www.saga.co.uk/magazine/health-wellbeing/conditions/cardiovascular/metabolic-syndrome

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.